# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Oren Livnat maintains ANI Pharmaceuticals (NASDAQ:ANIP) with a Buy and raises the price targ...
ANI continues to expect total company adjusted non-GAAP gross margin between 62% and 63% and the Company will continue to tax e...
ANI Pharmaceuticals (NASDAQ:ANIP) reported quarterly earnings of $1.21 per share which beat the analyst consensus estimate of $...
Guggenheim analyst Vamil Divan reiterates ANI Pharmaceuticals (NASDAQ:ANIP) with a Buy and maintains $77 price target.
U.S. annual sales for Baclofen Oral Suspension total approximately $39 million, according to IQVIA data.
ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced the launch of Levofloxacin Oral Solution, a generi...
Capital One analyst Timothy Chiang initiates coverage on ANI Pharmaceuticals (NASDAQ:ANIP) with a Overweight rating.
The Nasdaq 100 closed lower by around 1.5% on Friday. Investors, meanwhile, focused on some notable insider trades.